![Robert J. Towarnicki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert J. Towarnicki
Corporate Officer/Principal chez
Biotechnology Innovation Organization
Profil
Robert J.
Towarnicki currently works at Biotechnology Innovation Organization, as Member.
Mr. Towarnicki also formerly worked at Cell Pathways, Inc., as Chief Executive Officer, Nucleonics, Inc., as President & Chief Executive Officer from 2003 to 2009, SIRPant Immunotherapeutics, Inc., as President, Chief Executive Officer & Director, Merck & Co., Inc., as Principal, Integra LifeSciences Holdings Corp., as Principal, Collagen Corp., as Vice President, Quest Diagnostics Infectious Disease, Inc., as General Manager, and Pfizer Pharmaceuticals, Inc., as Operations Manager.
Mr. Towarnicki received his undergraduate degree and graduate degree from Villanova University.
Postes actifs de Robert J. Towarnicki
| Sociétés | Poste | Début |
|---|---|---|
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Corporate Officer/Principal | - |
Anciens postes connus de Robert J. Towarnicki
| Sociétés | Poste | Fin |
|---|---|---|
SIRPant Immunotherapeutics, Inc.
 SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops adoptive cell therapy | Directeur Général | 01/08/2024 |
Nucleonics, Inc.
 Nucleonics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA interference-based therapeutics | President | 04/12/2009 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur des opérations | - |
Collagen Corp.
 Collagen Corp. BiotechnologyHealth Technology Develops biomedical products from mammali | Corporate Officer/Principal | - |
Formation de Robert J. Towarnicki
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Integra LifeSciences Holdings Corp.
 Integra LifeSciences Holdings Corp. Medical SpecialtiesHealth Technology Develops, manufactures and markets medical devices, implants and biomaterials | Health Technology |
Cell Pathways, Inc.
 Cell Pathways, Inc. Pharmaceuticals: OtherHealth Technology Develops drugs to treat cancer | Health Technology |
Nucleonics, Inc.
Nucleonics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA interference-based therapeutics | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Collagen Corp.
Collagen Corp. BiotechnologyHealth Technology Develops biomedical products from mammali | Health Technology |
Villanova University
 Villanova University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quest Diagnostics Infectious Disease, Inc.
 Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Provides diagnostic services | Commercial Services |
Pfizer Pharmaceuticals, Inc.
Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops adoptive cell therapy | Health Technology |
